Overcoming immune-cell unresponsiveness in cancer by Guenther Lametschwandtner et al.
POSTER PRESENTATION Open Access
Overcoming immune-cell unresponsiveness
in cancer
Guenther Lametschwandtner1*, Monika Ermann2, Ina Sternberger3, Thomas Hesterkamp3, Isabella Haslinger1,
Hannes Mühleisen1, Manfred Schuster1, Hans Loibner1
From Society for Immunotherapy of Cancer 28th Annual Meeting
National Harbor, MD, USA. 8-10 November 2013
Despite significant recent progress, cancer immunother-
apy efficacies are still limited, since tumors can down-
modulate and escape the immune system by various
mechanisms. To overcome these limitations, we aimed
to identify low molecular weight molecules that can
enhance T cell reactivity in the context of otherwise
insufficient or suppressive stimulation. In an HTS cam-
paign, 80000 maximal diverse compounds were screened
on anti-CD3/CD28 stimulated human PBMCs using
enhancement of IL2 production as readout. The con-
firmed hit list contained 3 chemically independent ser-
ies, which enhanced the production of inflammatory
cytokines, especially IL-2, IFN-g and TNF-a, from TCR-
stimulated T cells, while lacking any agonist activity on
unstimulated T cells. The compound-mediated enhance-
ment of TCR-stimulation was also observed on the level
of T cell activation markers like CD25, CD69, CD71
and CD40L. In line with these observations, compounds
of these series enhanced the in vitro anti-tumor respon-
siveness of PBMCs against tumor cell lines, originating
from melanoma (M21), neuroblastoma (LAN) and
leukemia (K562). For MHC-positive tumor cells, refined
analysis demonstrated that compounds enhanced CD8 T
cell activation, resulting in selective tumor cell killing
while compounds in the absence of immune cells did
not affect tumor cell viability. In contrast, the PBMC-
response against K562 cells, which is a commonly used
NK cell target due to the lacking MHC-expression, was
mainly mediated by NK cells. Moreover, compounds
also enhanced IL-2 mediated NK cell proliferation
and cytokine (IFN-g, TNF-a) and effector molecule
(Granzyme B, Perforine) secretion. The activities
of these compounds were further confirmed in an
antigen-specific ex vivo T cell stimulation assay of
human PBMCs with Tetanus toxoid, which resulted in
enhanced proliferation of T cells. In addition, enhanced
IL-2 secretion by activated T cells led to consequently
increased NK cell activation and proliferation in
antigen-stimulated stimulated PBMCs. To enable future
assessment of compound activities in murine tumor
models in vivo, we have verified that compounds of all 3
series enhanced T cell activation and cytokine produc-
tion of TCR-stimulated murine T cells, while they had
no effect on unstimulated T cells. Together, we show
here the identification of a novel class of low molecular
weight compounds with drug-like properties that selec-
tively enhance activation of T and NK cells in the con-
text of antigen-specific and anti-tumor immunity with
high potential for development of improved tumor
immunotherapeutics.
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